Currently approved immunotherapies in NSCLC are monoclonal antibodies against the PD-1 (nivolumab, pembrolizumab, and cemiplimab), the PD-L1 (atezolizumab and durvalumab), or CTLA-4 proteins (ipilimumab). Here, CD274 is linked to non-small cell lung carcinoma.